Potential of Under- or Over-Delivery of Insulin Associated with Paradigm and Polyfin Insulin Infusion Sets
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 06/20/13 -- Medtronic Canada Ltd., in consultation with Health Canada, is providing updated safety information regarding Paradigm and Polyfin Insulin Infusion Sets manufactured by Unomedical A/S and Medtronic Minimed due to a potential problem that could result in incorrect delivery of insulin to the patient.
As a result of problems associated with this device, Medtronic has received two incident reports regarding the under- or over-delivery of insulin. The under- or over-delivery of insulin may cause hypoglycaemia (low blood sugar) or hypoglycaemia (high blood sugar), and in extreme cases, may cause the loss of consciousness or death.
Medtronic Canada Ltd. is distributing a letter to patients currently using this product that will explain how to avoid the incorrect delivery problem. The company is also notifying all affected pharmacies and health care professionals in order for them to help concerned patients use this device.
Patients who are concerned about this device should contact Medtronic Canada Ltd.'s 24-hour product support line at 1-800-646-4633. Health Canada would also like to remind patients who have health concerns related to their use of this device to speak with their health care professional.
Medtronic has identified the following models as being affected:
How to report side effects to health products:
Complaints involving medical devices can be reported to the Health Products and Food Branch Inspectorate by calling the toll-free hotline at 1-800-267-9675, or by writing to:
Egalement disponible en francais.
Contacts:
Media Inquiries:
Health Canada
613-957-2983
Public Inquiries:
613-957-2991
1-866-225-0709
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.06.2013 - 15:30 Uhr
Sprache: Deutsch
News-ID 1239005
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
Government & Administration
Anmerkungen:
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Potential of Under- or Over-Delivery of Insulin Associated with Paradigm and Polyfin Insulin Infusion Sets
"
steht unter der journalistisch-redaktionellen Verantwortung von
Health Canada (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
